FIELD: chemistry of natural compounds, biotechnology, pharmacology, medicine, oncology, pharmacy.
SUBSTANCE: invention relates to a medicinal formulation of angiogenesis inhibitor comprising active compound as liposome form wherein angiostatin or endostatin are used as an active component, and their truncated peptide fragments also, and an anti-angiogenic pharmaceutical composition used for treatment. Also, invention proposes a method for inhibition of tumor growth and metastasizing of malignant neoplasms associated with disorders in angiogenesis. Method involves administration of nontoxic therapeutically effective dose of pharmaceutical composition separately or in combination with adjuvant therapy with other antitumor preparations. Invention provides reducing rate of elimination of active compound (angiostatin, endostatin or their truncated fragments) from body and enhancing effectiveness of its therapeutic effect. Invention can be used for inhibition of tumor growth and metastasizing of malignant neoplasms.
EFFECT: enhanced and valuable medicinal properties of inhibitor.
7 cl, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATE POSSESSING SELECTIVE EFFECT WITH RESPECT TO CANCER TUMORS | 2005 |
|
RU2303997C2 |
| FUSED PROTEIN WITH EFFECT OF ANGIOGENESIS INHIBITOR | 2008 |
|
RU2372354C1 |
| ANTIANGIOGENIC MEDICINAL AGENT AND METHOD OF ITS PRODUCTION | 2009 |
|
RU2404783C1 |
| RECOMBINANT HYBRID POLYPEPTIDE, CAPABLE OF INHIBITING HUMAN ENDOTHELIAL CELL PROLIFERATION IN VITRO, AND METHOD FOR PRODUCTION THEREOF | 2011 |
|
RU2465283C1 |
| HUMAN ENDOSTATIN PREPARATION AND METHOD FOR PRODUCTION THEREOF | 2004 |
|
RU2278688C1 |
| ANTICANCER AGENT | 2012 |
|
RU2503450C1 |
| AGENT AND METHOD FOR TREATMENT AND PROPHYLAXIS OF ONCOLOGY DISEASES | 2005 |
|
RU2283658C1 |
| RECOMBINANT HYBRID INHIBITOR OF ANGIOGENESIS, AND ITS PRODUCTION METHOD | 2012 |
|
RU2499802C1 |
| ANTITUMOR PEPTIDE PREPARATION BASED ON ALPHA-FETOPROTEIN FRAGMENT, ITS CONJUGATE, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT OF HORMONE-DEPENDENT TUMORS | 2005 |
|
RU2285537C1 |
| ENHANCEMENT OF IMMUNE RESPONSES MEDIATED BY PROTEINS FUSED FROM ANTIBODY AND CYTOKINE BY METHOD OF COMBINED ADMINISTRATION OF ANGIOGENESIS INHIBITOR | 1999 |
|
RU2229305C2 |
